NEW YORK (GenomeWeb News) – The National Science Foundation is preparing the details of how it will parse out much of the $3 billion it received from the American Recovery and Reinvestment Act, which will include funding for standard grants, cutting-edge research, some previously declined proposals, and research infrastructure.

In a recent speech to employees about how the NSF will separate and spend the stimulus funds, Director Arden Bement said that the foundation will use those and other programs to distribute the $2 billion that is available for research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.